These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500 [TBL] [Abstract][Full Text] [Related]
3. CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas. Abate G; Tafuto S; Romano A; Gailli E; Corazzelli G Haematologica; 1992; 77(4):322-5. PubMed ID: 1385277 [TBL] [Abstract][Full Text] [Related]
4. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814 [TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology. Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856 [No Abstract] [Full Text] [Related]
6. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study. De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844 [TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
9. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report]. Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577 [TBL] [Abstract][Full Text] [Related]
11. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
12. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy. Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505 [TBL] [Abstract][Full Text] [Related]
13. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Sung HJ; Kim SJ; Seo HY; Sul HR; Choi JG; Choi IK; Park KH; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS Br J Haematol; 2006 Jul; 134(1):45-53. PubMed ID: 16803566 [TBL] [Abstract][Full Text] [Related]
14. [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype. Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583 [TBL] [Abstract][Full Text] [Related]
17. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group. Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723 [TBL] [Abstract][Full Text] [Related]
18. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560 [TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide, epirubicin, vincristine and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology. Comella P; Abate G; Fiore M; Di Finizio G; Polverino W; Muto P; Zarrilli D Haematologica; 1988; 73(6):509-12. PubMed ID: 3148514 [No Abstract] [Full Text] [Related]
20. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial. De Lena M; Maiello E; Lorusso V; Brandi M; Calabrese P; Romito S; Mazzei A; Marzullo F Med Oncol Tumor Pharmacother; 1989; 6(2):163-9. PubMed ID: 2473364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]